

PERSONAL DETAILS

Family name, First name: Kagiava Alexia

Researcher unique identifier(s) (ORCID): 0000-0002-3903-1299

Date of birth: 02/05/1983

Nationality: Norwegian

URL for web site: <https://www.cing.ac.cy/en/about-us/clinical-sciences/nce>

• Education and key qualifications

01/07/2011 PhD
Department of Biology, Aristotle University of Thessaloniki, Greece
Name of PhD Supervisor: George Theophilides

2007 Master Applied Genetics and Biotechnology
Department of Biology, Aristotle University of Thessaloniki, Greece

• Current position(s)

2025 –now Associate Senior Scientist/Group Head
Translational Neurotherapeutics Group, The Cyprus Institute of Neurology and Genetics

2015– now Faculty Associate
The Cyprus Institute of Neurology and Genetics

• Previous position(s)

2021-2025 Associate Scientist
Neuroscience Department, The Cyprus Institute of Neurology and Genetics

2012 – 2021 Post-doctoral fellow
Neuroscience Department, The Cyprus Institute of Neurology and Genetics

2006-2012 Researcher
Department of Biology, Aristotle University of Thessaloniki, Greece

RESEARCH ACHIEVEMENTS AND PEER RECOGNITION

Research achievements

RESEARCH SUPPORT

SMALL SCALE INFRASTRUCTURES/1222/0095 12/01/2023-05/30/2026

“Experimental Electrophysiology Unit”

The aim of this project is setup a new experimental electrophysiology unit in the CING premises to perform functional analysis in different disease mouse models and functional outcomes following gene therapy approaches in CNS and PNS.

Role: PI (737000€)

MDA952763, Charcot-Marie-Tooth Association and Muscular Dystrophy Association 10/01/2023-06/30/2026

“Nanoparticle-based gene delivery to Schwann cells for treating CMT disease”

The aim of this project is to develop a targeted nanoparticle to deliver the gene of interest to Schwann cells to treat CMT neuropathies.

Role: PI (\$299995)

COST action CA23106, “An Evolutionary View to Understanding Affective States across Species (AFFECT-EVO)”, 10/10/24-9/10/28

Role: Member of the Managerial Committee

MDA963041, Muscular Dystrophy Association 09/01/2022-11/30/2023

“Ultrasound-induced access of therapeutics to peripheral nerves”

The aim of this project is to study the efficacy of the focused ultrasound to facilitate the penetration of AAV vectors to the PNS to treat demyelinating neuropathies.

Role: PI (\$50000)

EXCELLENCE/0918/131, The Cyprus Research and Innovation Foundation 10/01/2019-03/31/2022

“Development of translatable cell targeted gene delivery to peripheral nerves”

The aim of this project is to develop minimal promoters in combination with new capsids to target Schwann cells and treat CMT peripheral neuropathies.

Role: PI (250000€)

CULTURE/BP-NE/0416/07, The Cyprus Research and Innovation Foundation, 05/01/2017-07/31/2019

“Evaluation of gene therapy in a CMT1X model with advanced peripheral neuropathy”

The aim of this project is to examine whether repeat injection could result in higher expression of the desired gene and expand the gene therapy approach at 6 months of age.

Role: PI (35000€)

PATENTS FILED

- Inventor in the patent WO2016020504A1 "Oxaliplatin-induced neurotoxicity in the peripheral nerve fibres of the mouse is mediated through connexin29 hemichannels, can be prevented by the gap junction blocker octanol"
- Contributor in the patent EP2667863A1
- Inventor in the patent WO2020245169A1 “AAV vectors with myelin protein zero promoter and uses thereof for treating Schwann cell-associated diseases like Charcot-Marie-Tooth disease

PUBLICATIONS

1. **Kagiava A** and Kleopa KA; “Facing the challenge of effective dosing, safety, and timing of intrathecal gene therapy for neurological disorders”. *eBiomedicine*. 2025 Nov 24;123:106045. doi:10.1016/j.ebiom.2025.106045
2. Melina Christou, Irene Sargiannidou, Revekka Papacharalambous, Jan Richter, Christina Tryfonos, Christina Christodoulou, **Alexia Kagiava**, Kleopas A. Kleopa.; “A dose escalation and safety study of AAVrh10-mediated Schwann cell-targeted gene therapy for CMT1X” *Neurotherapeutics* 2025 Apr;22(3):e00568. doi: 10.1016/j.neurot.2025.e00568. **Co-last author**
3. Georgiou E., **Kagiava A.**, Sargiannidou I., Schiza N., Richter J., Tryfonos C., Heslegrave A., Zetterberg H., Christodoulou C., Kleopa K.A.; “AAV9-mediated *SH3TC2* gene replacement therapy targeted to Schwann cells for the treatment of CMT4C”. *Mol Ther*. 2023 Nov 1;31(11):3290-3307. doi: 10.1016/j.ymthe.2023.08.020.
4. **Kagiava A.**, Karaiskos C., Lapathitis G., Heslegrave A., Sargiannidou I., Zetterberg H., Bosch A., Kleopa K.A.; “Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy”. *Mol. Ther Methods Clin Dev*. 2023 Aug 2;30:377-393. doi: 10.1016/j.omtm.2023.07.011
5. Stavrou M, **Kagiava A**, Sargiannidou I, Georgiou E, Kleopa KA; “Charcot-Marie-Tooth neuropathies: current gene therapy advances and the route towards translation”. *J Peripher Nerv Syst*. 2023 Jun;28(2):150-168. doi: 10.1111/jns.12543
6. Stavrou M., **Kagiava A.**, Choudury S., Jennings M.J. , Wallace L.M. , Fowler A.M. , Heslegrave A. , Richter J. , Tryfonos C. , Christodoulou C. , Zetterberg H. , Horvath R. , Harper S.Q , Kleopa K.A. A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice. *J Clin Invest*. 2022 Jul 1;132(13):e159814
7. Jennings MJ, **Kagiava A**, Vendredy L, Spaulding EL, Stavrou M, Hathazi D, Grüneboom A, De Winter V, Gess B, Schara U, Pogoryelova O, Lochmüller H, Borchers CH, Roos A, Burgess RW,

- Timmerman V, Kleopa KA, Horvath R. NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice. *Brain*. 2022 Feb 10: awac055.
8. Fella E., Papacharalambous R., Kynigopoulos D., Ioannou M., Derua R., Christodoulou C., Stylianou M., Karaiskos C., **Kagiava A.**, Gerasimou P., Pierides C., Kyriakou M., Koumas L., Costeas P. and Panagiotou E. Pharmacological activation of the C5a receptor leads to stimulation of the beta-adrenergic receptor and alleviates cognitive impairment in a murine model of familial Alzheimer's disease. *Front. Immunol.* 2022 Aug 26;13:947071
 9. **Kagiava A.**, Richter J., Tryfonos C., Leal-Julìà M., Sargiannidou I., Christodoulou C., Bosch A. and Kleopa KA; "Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery". *Sci Rep.* 2021 Dec 2;11(1):23358. doi: 10.1038/s41598-021-02694-1.
 10. Stavropoulos F, Sargiannidou I, Potamiti L, **Kagiava A.**, Panayiotidis MI, Bae JH, Yeom SC, Lee JY, Kleopa KA; "Aberrant Mitochondrial Dynamics and Exacerbated Response to Neuroinflammation in a Novel Mouse Model of CMT2A" *Int J Mol Sci.* 2021 Oct 26;22(21):11569. doi: 10.3390/ijms222111569
 11. Stavrou M, Sargiannidou I, Georgiou E, **Kagiava A.**, Kleopa KA; "Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies"; *Int J Mol Sci.* 2021 Jun 3;22(11):6048. doi: 10.3390/ijms22116048.
 12. **Alexia Kagiava**, Christos Karaiskos, Jan Richter, Christina Tryfonos, Matthew Jennings, Amanda Heslegrave, Irene Sargiannidou, Marina Stavrou, Henrik Zetterberg, Mary Reilly, Christina Christodoulou, Rita Horvath, Kleopas Kleopa; "AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy". *Gene Therapy.* 2021 Mar 10. doi: 10.1038/s41434-021-00250-0
 13. Sargiannidou I, **Kagiava A.**, Kleopa KA. "Gene therapy approaches targeting Schwann cells for demyelinating neuropathies". *Brain Res.* 2020 Feb 1;1728:146572. doi: 10.1016/j.brainres.2019.146572.
 14. **Kagiava A.**, Richter J, Tryfonos C, Karaiskos C, Heslegrave AJ, Sargiannidou I, Rossor AM, Zetterberg H, Reilly MM, Christodoulou C, Kleopa KA. "Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X"; *Hum Mol Genet.* 2019 doi: 10.1093/hmg/ddz199
 15. Schiza N, Georgiou E, **Kagiava A.**, Médard JJ, Richter J, Tryfonos C, Sargiannidou I, Heslegrave AJ, Rossor AM, Zetterberg H, Reilly MM, Christodoulou C, Chrast R, Kleopa KA. "Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy"; *Brain, Volume 142, 2019 Pages 1227-1241.* doi: 10.1093/brain/awz064
 16. Kleopa K.A., **Kagiava A.**, Sargiannidou I. "Gene Therapy for CMT Inherited Neuropathy". *Muscle Gene Therapy, 2018,* doi.org/10.1007/978-3-030-03095-7_35
 17. **Kagiava A.** and Kleopa K.A. "Intrathecal Delivery of Viral Vectors for Gene Therapy"; *Methods Mol Biol. Volume 1791, 2018, Pages 277-285.* doi: 10.1007/978-1-4939-7862-5_22.
 18. **Kagiava A.**, Karaiskos C., Richter J., Tryfonos C., Lapathitis G., Sargiannidou I., Christodoulou C., Kleopa K.A. "Intrathecal gene therapy in mouse models expressing CMT1X mutations"; *Hum Mol Genet. Volume 27, Apr 2018, Pages 1460-1473* doi: 10.1093/hmg/ddy056
 19. Kyriakoudi S, Sargiannidou I, **Kagiava A.**, Olympiou M, Kleopa KA. "Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1X"; *Hum Mol Genet. Volume 26, May 2017, Pages 1622-1633* doi: 10.1093/hmg/ddx064
 20. Georgiou E, Sidiropoulou K, Richter J, Papanephytou C, Sargiannidou I, **Kagiava A.**, von Jonquieres G, Christodoulou C, Klugmann M, Kleopa KA. "GJC2/Cx47 gene delivery to oligodendrocytes reestablishes gap junctions and provides therapeutic benefit in a leukodystrophy model"; *Brain, Volume 140, March 2017, Pages 599-616.* doi: 10.1093/brain/aww351
 21. Olympiou M, Sargiannidou I, Markoullis K, Karaiskos C, **Kagiava A.**, Kyriakoudi S, Abrams CK, Kleopa KA. Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease. *Acta Neuropathol Commun. Volume 4, September 2016, Pages 95.* doi: 10.1186/s40478-016-0369-5.
 22. **Kagiava A.**, Sargiannidou I., Theophilidis G., Karaiskos C., Richter J., Bashirdes S., Schiza N., Nearchou M., Christodoulou C, Scherer SS, Kleopa KA. "Intrathecal gene delivery for the treatment of inherited peripheral neuropathies"; *PNAS, Volume 113, April 2016, Pages 2421-9.* doi: 10.1073/pnas.1522021113
 23. Zafeiridou G, Spilioti M, **Kagiava A.**, Krikonis K, Kosmidis EK, Karlovasitou A, Kimiskidis VK. "Differential effects of lacosamide, phenytoin and topiramate on peripheral nerve excitability: An ex vivo electrophysiological study"; *NeuroToxicology, Volume 52, November 2015, Pages 57-63.* doi: 10.1016/j.neuro.2015.10.016.

24. **Kagiava A.**, Theophilidis G., Sargiannidou I., Kyriacou K., Kleopas K.A.; “Oxaliplatin-induced neurotoxicity is mediated through gap junction hemichannels and can be prevented by octanol”; *Neuropharmacology*, Volume 97, October 2015, Pages 289-305 doi: 10.1016/j.neuropharm.2015.05.021.
25. Sargiannidou I, **Kagiava A.**, Bashiardes S, Richter J, Christodoulou C, Scherer SS, Kleopa KA. “Intraneural GJB1 gene delivery improves nerve pathology in a model of CMT1X”; *Annals of Neurology*. Volume 78, Issue 2, August 2015, Pages 303-316 doi: 10.1002/ana.24441
26. Schiza N., Sargiannidou I., **Kagiava A.**, Karaiskos C., Nearchou M., Kleopa K.A.; “Transgenic replacement of Cx32 in gap junction deficient oligodendrocytes rescues the phenotype of a hypomyelinating leukodystrophy model”; *Human Molecular Genetics*. Volume 24, Issue 7, 2015, Pages 2049-2064 doi: 10.1093/hmg/ddu725
27. **Kagiava A.**, Sargiannidou I., Bashiardes S., Richter J., Schiza N., Christodoulou C., Gritti A., Kleopa K.A.; “Gene delivery targeted to oligodendrocytes using a lentiviral vector”; *The Journal of Gene Medicine*. Volume 16, Issue 11-12, 2014, Pages 364-373 doi: 10.1002/jgm.2813
28. **Kagiava A.** and Theophilidis G.; “Assessing the permeability of the rat sciatic nerve perineurium against compounds with local anaesthetic activity. An *ex vivo* electrophysiological study”; *Toxicology Mechanisms and Methods*. Volume 23, Issue 8, 2013, Pages 634-640 doi: 10.3109/15376516.2013.825826
29. **Kagiava A.**, Kosmidis E.K. and Theophilidis G.; “Oxaliplatin-induced Hyperexcitation of Rat Sciatic Nerve Fibers: An Intra-axonal Study”; *Anticancer Agents Med Chem*. Volume 13, Issue 2, February 2013, Pages 373-379
30. Papachristoforou A, **Kagiava A.**, Papaefthimiou C, Termentzi A, Fokialakis N, Skaltsounis AL, Watkins M, Arnold G, Theophilidis G. “The bite of the honeybee: 2-heptanone secreted from honeybee mandibles during a bite acts as a local anaesthetic in insects and mammals”; *PLoS One*. Volume 7, Issue 10, 2012, Pages e47432 doi: 10.1371/journal.pone.0047432
31. **Kagiava A.**, Aligizaki A., Katikou P., Theophilidis G. and Nikolaidis G.; “Assessing the neurotoxic effects of palytoxin and ouabain, both Na⁺/K⁺-ATPase inhibitors, on the myelinated sciatic nerve fibres of the mouse: an *ex vivo* electrophysiological study”; *Toxicon*, Volume 59, Issue 3, March 2012, Pages 416-426 doi: 10.1016/j.toxicon.2011.12.007
32. **Kagiava A.** and Theophilidis G.; “High concentrations of dichloroacetate (DCA) have minor effects on the mammalian nerve fibres. An *ex vivo* study”; *Anti-Cancer Drugs*, Volume 22, Issue 3, March 2011, Pages 273-276 doi: 10.1097/CAD.0b013e3283425888
33. Zalachoras I., **Kagiava A.**, Vokou D., and Theophilidis G.; “Assessing the local anesthetic effect of five essential oil constituents”; *Planta Medica*, Volume 76, Issue 15, October 2010, Pages 1647-1653 doi: 10.1055/s-0030-1249956
34. **Kagiava A.**, Tsingotjidou A., Emmanouilides C. and Theophilidis G; “The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat”; *NeuroToxicology*, Volume 29, Issue 6, November 2008, Pages 1100-1106 doi:10.1016/j.neuro.2008.09.005
35. Moschou M., Papaefthimiou C., **Kagiava A.**, Antonopoulou E. and Theophilidis G.; “*In vitro* assessment of the effects of cadmium and zinc on mammalian nerve fibres”; *Chemosphere*, Volume 71, Issue 10, May 2008, Pages 1996-2002 doi:10.1016/j.chemosphere.2008.01.070
36. Andreou A., Dabarakis N., **Kagiava A.**, Kosmidis E.K., Geronikaki A. and Theophilidis G.; “Assessing the effects of three dental impression materials on the isolated sciatic nerve of rat and frog”; *Toxicology in Vitro*, Volume 21, Issue 1, February 2007, Pages 103-108 doi:10.1016/j.tiv.2006.07.014

PEER RECOGNITION

Awards

2023: Meritorious Abstract Travel Award from the American Society of Gene&Cell Therapy (ASGCT) at the ASGCT 26th Annual Meeting “AAVrh10 Schwann cell targeted gene replacement therapy for CMT1X demyelinating neuropathy” (16-20 May 2023)

2016: Awarded with the Panos Ioannou Junior Scientist Award

- 2014:** Travel grant from FENS/IBRO for poster presentation at the 9th Forum of European Neuroscience Societies, Milan, Italy, "Gene delivery targeted to myelinating cells to treat inherited neuropathies and leukodystrophy" (5-9 July 2014)
- 2013:** Travel grant from PNS Society for poster presentation in the PNS Biennial Meeting, Saint-Malo, Brittany, France, "Oxaliplatin-induced hyperexcitation of rat sciatic nerve fibers: an intra-axonal study" (29 June -3 July 2013)
- 2011:** Second award for Oral presentation in 17th Hellenic Conference of Clinical Oncology, Athens, Greece, "Effects of oxaliplatin on the action potential of nerve axons of peripheral nervous system" (April 14-16 2011)
- 2010:** Travel grant from FENS/IBRO for poster presentation in 7th Forum of European Neuroscience Societies, Amsterdam, Netherlands, "Assessment of the neurotoxic effects of palytoxin and palytoxin-like compounds produced by *Ostreopsis* species, affecting the Na⁺/K⁺-ATPase pump, using the isolated mouse sciatic nerve" (July 3-7 2010)
- 2006:** Travel grant for attending the Onassis Foundations Science Lectures Series «**Brain Plasticity: From Molecules to Behavior**» (17-21 July 2006, Heraklion-Crete). Invited speaker: Eric Kandel Nobel Prize winner
- 2007:** Travel grant for attending the Onassis Foundations Science Lectures Series «**Channels and Channelopathies**» (2-6 July 2007, Heraklion-Crete). Invited speaker: Peter Agre Nobel Prize winner

Memberships

- 2005-present: Member of Hellenic Society of Neuroscience (HSN)
- 2005-present: Member of Federation of European Neuroscience Societies (FENS)
- 2012-present: Member of the Peripheral Nerve Society (PNS)
- 2017-present: Member of the Society for Neuroscience (SfN)
- 2019-present: Member of the European Society of Gene and Cell Therapy (ESGCT)
- 2021-present: Member of the American Society of Gene and Cell Therapy (ASGCT)
- 2022-present: Member of the Hellenic Society of Gene Therapy and Regenerative Medicine
- 2024: Member of the European CMT Research Association

Participation in research projects

- 2019-2022: Researcher in the project "A translatable gene therapy for CMT1X" funded by the Muscular Dystrophy Association and the CMT Association
- 2017-2019: Researcher in the project "Expanding the gene therapy approach for treating CMT1X" funded by the Muscular Dystrophy Association and the CMT Association
- 2013-2017: Researcher in the project "Developing gene therapy for inherited neuropathy" funded by the Muscular Dystrophy Association
- 2012-2013: Researcher in the project "Gene Therapy for Hypomyelinating Leukodystrophy" funded by the European Leukodystrophy Association
- 2011: Researcher in the project "Assessment of the effects of lacosamide on the nerve fibers of the rat sciatic nerve. An electrophysiological study"
- 2010-2012: Participation in the research project funded by VITA Limited, United Kingdom (Europe) for the assessment of the effects of different acaricides on the rat sciatic nerve.
- 2010: Researcher in the project "Phytoplankton monitoring in mussel production areas of Pieria Prefecture with emphasis on toxic microalgae"
- 2008-2010: Researcher in the project "Toxic microalgae monitoring in bivalve mollusks production and fisheries areas of Thessaloniki Prefecture"
- 2008: Researcher in the project "Assessing the toxicity of the extensively used insecticide imidacloprid on the central and peripheral nervous system of mammalians" Greek-Turkey, Scientific Cooperation, supported by the Greek General Secretariat of Research and Technology. Ministry of Development. Greece
- 2007-2008: Researcher in the project "Human networks of research and technological training"-

"Human network for training in the field of bioeffective foods".

- 2006-2007: Researcher in the project "Development of *in vitro* neurophysiological methods for the assessment of the action of neurotoxic pesticides and other chemical compounds on the central and peripheral nervous system of animals (insects and mammals)" Greek Ministry of Education and Religion (EPEAEK, PYTHAGORAS II)

Other contributions to the research community

2024-2026: Vice chair of the PNS Junior Committee

2024-2026: Member of the PNS Scientific Program Committee

2024-2026: Member of the PNS Education Committee

2024-2026: Member of the ASGCT's Musculo-Skeletal Gene and Cell Therapy Committee

2023 PNS Annual Meeting. Mini-Symposium organizer

Title: Emerging Gene Therapies for Peripheral Neuropathies from the Bench to Translation

Organizer: Alexia Kagiava

Speakers: Marina Stavrou, PhD; Suzan Boutary, PhD; Kathrin Meyer

Teaching Experience:

2015-present: Teaching at the Neuroscience course (NEURO101) at CING

2012-present: Co-Supervision of MSc (5 students) and PhD students (2 students) (total of years supervising at CING: 6)

2008-2010: Teaching assistant in the Laboratory Practical Exercises of the Animal Physiology I and II and Environmental and Comparative Physiology

2006-2011: Supervision of undergraduate (8 students) and postgraduate students (2 MSc and 1 PhD) at the Laboratory of Neurophysiology of the Aristotle University of Thessaloniki

Conferences

1. **A Kagiava**, N Schiza, J D Graef, I Sargiannidou, K A Kleopa; "Efficacy and safety of AAVrh10 and AAVrh74 viral vectors targeting Schwann cells in PNS tissues of Non-Human Primates"; 2025 PNS Annual Meeting (May 2025, Edinburgh, UK) Oral presentation
2. N Schiza, Lytridou A., J D Graef, M. Xinari, I Sargiannidou, Kombou M, **A Kagiava**, K A Kleopa; "AAVrh10 and AAVrh74 Schwann cell targeted gene replacement therapy for CMT1X demyelinating neuropathy"; 2025 PNS Annual Meeting (May 2025, Edinburgh, UK)
3. N Schiza, J D Graef, I Sargiannidou, **A Kagiava**, K A Kleopa; Biodistribution and safety of AAVrh10 and AAVrh74 viral vectors targeting Schwann cells in PNS tissues of Non-Human Primates. ESGCT Annual Meeting 2024 (October 2024, Rome, Italy). Presenting author
4. N Schiza, Lytridou A., J D Graef, I Sargiannidou, Kombou M, **A Kagiava**, K A Kleopa; AAVrh10 and AAVrh74 Schwann cell targeted gene replacement therapy for CMT1X demyelinating neuropathy. ESGCT Annual Meeting 2024 (October 2024, Rome, Italy)
5. Kombou M., Antoniou A., Damianou C., Kleopa K.A., **Kagiava A** "Ultrasound-Induced Enhanced Access of Therapeutics to Peripheral Nerves of A Demyelinating Charcot-Marie-Tooth Mouse Model"; 2024 PNS Annual Meeting (June 2024, Montreal, Canada) Oral presentation
6. **Kagiava A.**, Christou M., Sargiannidou I., Kleopa KA; AAVrh10 Schwann cell targeted gene replacement therapy for CMT1X demyelinating neuropathy. ASGCT Annual Meeting 2023 (May 2023, Los Angeles, USA)
7. **Kagiava A.** CMT X: clinical to basic biology. 2023 PNS Annual Meeting (June 2023, Copenhagen, Denmark) Invited speaker for the Education Day
8. Georgiou E., **Kagiava A.**, Sargiannidou I., Papacharalambous R., Richter J., Tryfonos C., Christodoulou C., Kleopa K. "A dose-escalation and safety study of AAV9-mediated gene replacement therapy for the treatment of CMT4C". 2023 PNS Annual Meeting (June 2023, Copenhagen, Denmark)

9. **Kagiava A.**, Christou M., Sargiannidou I., Kleopa KA; A dose-escalation and safety study of AAVrh10-mediated cell-targeted gene replacement in a model of CMT1X demyelinating neuropathy. 2023 PNS Annual Meeting (June 2023, Copenhagen, Denmark)
10. Giorgos Solomonides, Jan Richter, Christina Tryfonos, **Alexia Kagiava**, Christina Christodoulou. Optimising Adeno-Associated Viral Vector Mediated Gene Delivery to the Central Nervous System. 10th Anniversary International Multithematic Bio-Medical Congress (IMBMC) (November 3-5, 2022, Nicosia Cyprus)
11. **Kagiava, W.** Casy C. Trygg, S.E. Braun, S.J. Gray, K.A. Kleopa. AAV9 biodistribution and expression in the PNS of Non-Human Primates. 29th ESGCT meeting (October 11-14 2022, Edinburgh, UK)
12. **Alexia Kagiava**, Xin Chen, Widler Casy, Thomas Dong, Thomas J. McCown, Steven J. Gray, Kleopas A. Kleopa. Novel AAV variants targeting Schwann cells. ASGCT Annual Meeting 2022 (May 2022, Washington DC, USA)
13. Matthew Jennings, **Alexia Kagiava**, Leen Vendredy, Emily Spaulding, Marina Stavrou, Anika Grüneboom, Vicky De Winter, Burkhard Gess, Ulrike Schara, Oksana Pogoryelova, Hanns Lochmuller, Christoph Borchers, Andreas Roos, Robert Burgess, Vincent Timmerman, Kleopas Kleopa, Rita Horvath. NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth Disease in patients and mice. 2022 PNS Annual Meeting (May 2022, Miami, USA)
14. **Alexia Kagiava**, Christos Karaiskos, George Lapathitis, Irene Sargiannidou, Assumpció Bosch, Kleopas Kleopa. AAV9-mediated post-onset gene replacement therapy benefits transgenic models of CMT1X neuropathy; 2022 PNS Annual Meeting (May 2022, Miami, USA)
15. Marina Stavrou, **Alexia Kagiava**, Sarah Choudury, Jan Richter, Christina Tryfonos, Christina Christodoulou, Scott Harper, Kleopas A. Kleopa. “AAV9-microRNA mediated gene silencing improves the phenotype of a CMT1A mouse model”; 2021 PNS Annual Meeting (June 2021 Virtual Meeting)
16. **Kagiava A**, Karaiskos C, Lapathitis G, Sargiannidou I, Bosch A, Kleopa KA. “AAV9 gene replacement therapy in two mutant mouse models of CMT1X demyelinating neuropathy”; 2021 PNS Annual Meeting (June 2021 Virtual Meeting) *Oral poster*
17. **Alexia Kagiava**, Jan Richter, Christina Tryfonos, Irene Sargiannidou, Assumpció Bosch, Kleopas Kleopa. “Efficacy of Two AAV Serotypes to target Schwann Cells After Intrathecal and Intravenous Delivery”; 2021 PNS Annual Meeting (June 2021 Virtual Meeting)
18. Matthew Jennings, **Alexia Kagiava**, Leen Vendredy, Emily Spaulding, Marina Stavrou, Vicky De Winter, Burkhard Gess, Christoph Borchers, Andreas Roos, Robert Burgess, Vincent Timmerman, Kleopas Kleopa, Rita Horvath. “Combining the power of patients and mouse models to identify biomarkers in CMT” 2020 PNS Annual Meeting (June 2020 Virtual Meeting)
19. **Kagiava A.**, Karaiskos C., Schiza N., Richter J., Tryfonos C., Sargiannidou I., Christodoulou C., Kleopa K.A. “Gene replacement therapy for peripheral demyelinating neuropathies”; 1st Advanced Therapy Science Meeting (1ATSM) (November 25-26, 2019, Berlin-Germany)
20. Stavrou M., Sargiannidou I., **Kagiava A.**, Richter J., Tryfonos C., Christodoulou C., Karaiskos C., Lapathitis G., Kleopa KA. “Testing an shRNA gene silencing approach in a mouse model of Charcot-Marie-Tooth Disease Type 1A”; 2019 PNS Annual Meeting (June 22-26, 2019, Genova-Italy)
21. **Kagiava A.**, Karaiskos C., Richter J., Tryfonos C., Rossor A., Reilly M.M., Sargiannidou I., Christodoulou C., Kleopa K.A “Gene replacement therapy for CMT1X neuropathy”; 2019 PNS Annual Meeting (June 22-26, 2019, Genova-Italy) *Oral presentation and poster*
22. **Kagiava A.**, Karaiskos C., Richter J., Tryfonos C., Rossor A., Reilly M.M., Sargiannidou I., Christodoulou C., Kleopa K.A. Gene therapy after onset of neuropathy provides therapeutic benefit in a model of CMT1X. 2019 AAN Annual Meeting (May 4-10, Philadelphia, USA).
23. **Kagiava A.**, Richter J., Tryfonos C., Karaiskos C., Sargiannidou I., Christodoulou C., Kleopa K.A. “Gene replacement therapy for CMT1X neuropathy”; 7th International Conference of the Cyprus Society of Human Genetics (December 7-8, 2018, Nicosia Cyprus)
24. Stavrou M., Sargiannidou I., **Kagiava A.**, Richter J., Tryfonos C., Karaiskos C., Lapathitis G. and Kleopa K.A. “A Gene Silencing Approach to Treat Charcot-Marie-Tooth Disease Type 1A”; 6th International Multithematic Bio-Medical Congress (IMBMC) (November 15-17, 2018, Nicosia Cyprus)
25. **Kagiava A.**, Richter J., Tryfonos C., Karaiskos C., Sargiannidou I., Christodoulou C., Kleopa K.A. “Gene replacement therapy for CMT1X neuropathy”; 6th International Multithematic Bio-Medical Congress (IMBMC) (November 15-17, 2018, Nicosia Cyprus) *Oral poster*

26. Schiza N., Georgiou E., Richter J, Tryfonos C, **Kagiava A.**, Sargiannidou I., Christodoulou C, Kleopa K.A. “A gene therapy approach for treating Charcot-Marie-Tooth disease type 4C”; 6th International Multithematic Bio-Medical Congress (IMBMC) (November 15-17, 2018, Nicosia Cyprus)
27. Stavrou M., Sargiannidou I., **Kagiava A.**, Richter J., Tryfonos C., Karaiskos C., Lapathitis G. and Kleopa K.A. “A Gene Silencing Approach to Treat Charcot-Marie-Tooth Disease Type 1A”; 2018 PNS Annual Meeting (July 22-25, 2018, Baltimore-USA)
28. **Kagiava A.**, Richter J., Tryfonos C., Karaiskos C., Sargiannidou I., Christodoulou C., Kleopa K.A. “Gene replacement therapy for CMT1X neuropathy”; 2018 PNS Annual Meeting (July 22-25, 2018, Baltimore-USA)
29. Schiza N., Georgiou E., Richter J, Tryfonos C, **Kagiava A.**, Sargiannidou I., Christodoulou C, Kleopa K.A. “A gene therapy approach for treating Charcot-Marie-Tooth disease type 4C”; 2018 PNS Annual Meeting (July 22-25, 2018, Baltimore-USA)
30. Tympanidou M, **Kagiava A**, Kleopa KA. “The functional role of connexins in peripheral myelinated fibers in health and disease”; 27th meeting of the Hellenic Society for Neuroscience (December 8-10; 2017, Athens, Greece)
31. Schiza N, Richter J, Tryfonos C, **Kagiava A**, Sargiannidou I, Christodoulou C, Kleopa KA. “Gene therapy approach using a lentiviral vector for treating Charcot-Marie-Tooth Type 4C”; 27th meeting of the Hellenic Society for Neuroscience (December 8-10; 2017, Athens, Greece)
32. **Kagiava A.**, Karaiskos C., Richter J., Tryfonos C., Lapathitis G., Sargiannidou I., Christodoulou C., Kleopa K.A. “Development of an intrathecal gene therapy approach in models of CMT1X inherited neuropathy”; 27th meeting of the Hellenic Society for Neuroscience (December 8-10; 2017, Athens, Greece)
33. **Kagiava A.**, Karaiskos C., Richter J., Tryfonos C., Lapathitis G., Sargiannidou I., Christodoulou C., Kleopa KA.; “Expanding the gene therapy approach for treating CMT1X inherited neuropathy”; Neuroscience 2017, Annual Meeting of the SfN (November 11-15; Washington DC, USA)
34. Schiza N., Markoullis K., Richter J., Tryfonos C., **Kagiava A.**, Sargiannidou I., Christodoulou C., Kleopa KA.; “A gene therapy approach for treating CMT4C neuropathy”; 2017 PNS Annual Meeting (July 8-12, 2017, Sitges-Spain)
35. **Kagiava A.**, Karaiskos C., Richter J., Tryfonos C., Lapathitis G., Sargiannidou I., Christodoulou C., Kleopa KA.; “Intrathecal gene therapy in different mutant mouse models of CMT1X”; 2017 PNS Annual Meeting (July 8-12, 2017, Sitges-Spain) *Oral poster*
36. Tympanidou M., **Kagiava A.**, Kleopa KA. “The functional role of connexins in peripheral myelinated fibers”; 2017 PNS Annual Meeting (July 8-12, 2017, Sitges-Spain)
37. Kyriakoudi S., Sargiannidou I., **Kagiava A.**, Kleopa KA., “In vitro screening for interactions between virally delivered Cx32 and neuropathy-associated mutants: towards a gene therapy for CMT1X”; 6th International Charcot-Marie-Tooth And Related Neuropathy Consortium (Cmtr) Meeting (September 8-10, 2016, Venice-Italy)
38. **Kagiava A.**, Karaiskos C., Richter J., Sargiannidou I., Christodoulou C., Kleopa KA., “Intrathecal gene therapy in a neuropathy model expressing a CMT1X mutation”; 6th International Charcot-Marie-Tooth and Related Neuropathy Consortium (Cmtr) Meeting (September 8-10, 2016, Venice-Italy), *Oral presentation*
39. **Kagiava A.**, Sargiannidou I., Bashiardes S., Richter J., Schiza N., Christodoulou C., Kleopa K.A “Gene delivery targeted to myelinating cells to treat inherited neuropathies” ; XII European Meeting on Glial Cells in Health and Disease (July 15 - 18, 2015, Bilbao-Spain)
40. Kleopa KA, **Kagiava A**, Bashiardes S, Richter J, Christodoulou C, Sargiannidou I: Intraneural and intrathecal gene delivery using a Schwann cell targeted lentiviral vector for treating inherited demyelinating neuropathies. Accepted for oral presentation at the 1st European Academy of Neurology Meeting in Berlin, June 20-23, 2015.
41. Olympiou M., Sargiannidou I., **Kagiava A.**, Georgiou E., Karaiskos C., Kleopa K.A.; “Modeling central nervous system phenotypes of X-linked Charcot-Marie Tooth by lipopolysaccharide-induced”; 12th International Congress of Neuroimmunology (November 9-13, 2014, Mainz-Germany)
42. Schiza N., Sargiannidou I., **Kagiava A.**, Karaiskos C., Kleopa K.A.; “Transgenic replacement of oligodendrocyte gap junctions rescues the phenotype of a hypomyelinating leukodystrophy model”; 9th FENS Forum; 5-9 July 2014; Milan, Italy.
43. **Kagiava A.**, Sargiannidou I., Bashiardes S., Richter J., Schiza N., Christodoulou C., Gritti A., Kleopa K.A.; “Gene delivery targeted to myelinating cells to treat inherited neuropathies and leukodystrophy”; 9th FENS Forum; 5-9 July 2014; Milan, Italy.

44. Kleopa KA, **Kagiava A**, Bashardes S, Richter J, Christodoulou C, Gritti A, Sargiannidou I: “Gene Therapy in a Model of CMT1X Neuropathy using a Lentiviral Vector”; American Academy of Neurology 2014 Annual Meeting, Philadelphia, PA, April 29, 2014. *Oral presentation*
45. **Kagiava A.**, Sargiannidou I., Bashiardes S., Richter J., Schiza N., Christodoulou C., Gritti A., Kleopa K.A.; “Gene delivery targeted to myelinating cells to treat inherited neuropathies and leukodystrophy”; 4th International Conference of the Cyprus Society of Human Genetics; (October 10-11, 2014, Nicosia-Cyprus); *Oral presentation*
46. Schiza N., Sargiannidou I., **Kagiava A.**, Karaiskos C., Nearchou M., Kleopa K.A.; “Transgenic replacement of oligodendrocyte gap junctions rescues the phenotype of a hypomyelinating leukodystrophy model”; 4th International Conference of the Cyprus Society of Human Genetics; (October 10-11, 2014, Nicosia-Cyprus)
47. Olympiou M., Sargiannidou I., **Kagiava A.**, Georgiou E., Karaiskos C., Kleopa K.A.; “Modeling central nervous system phenotypes of X-linked Charcot-Marie Tooth by lipopolysaccharide-induced”; 4th International Conference of the Cyprus Society of Human Genetics; (October 10-11, 2014, Nicosia-Cyprus)
48. Sargiannidou I., **Kagiava A.**, Bashiardes S., Richter J., Schiza N., Christodoulou C., Kleopa K.A.; “Intraneural gene delivery improves nerve pathology in a mouse model of X-linked CMT”; (October 10-11, 2014, Nicosia-Cyprus)
49. Sargiannidou I., **Kagiava A.**, Bashiardes S., Richter J., Schiza N., Christodoulou C., Gritti A., Kleopa K.A.; “Efficient lentiviral gene delivery to schwann cells”; 10th Euroglia Meeting; 3-6 July 2013; Berlin, Germany.
50. **Kagiava A.**, Sargiannidou I., Bashiardes S., Richter J., Schiza N., Christodoulou C., Gritti A., Kleopa K.A.; “Oligodendrocyte-targeted gene therapy to treat leukodystrophy”. 10th Euroglia Meeting; 3-6 July 2013; Berlin, Germany.
51. Sargiannidou I., **Kagiava A.**, Bashiardes S., Richter J., Schiza N., Christodoulou C., Gritti A., Kleopa K.A.; “Efficient lentiviral gene delivery to schwann cells”; 2013 Biennial Meeting of the Peripheral Nerve Society; 29 June -3 July 2013; **Saint-Malo – Brittany-France**
52. **Kagiava A.** and Theophilidis G.; “Oxaliplatin-induced hyperexcitation of rat sciatic nerve fibers: an intra-axonal study”; 2013 Biennial Meeting of the Peripheral Nerve Society; 29 June -3 July 2013; **Saint-Malo – Brittany-France**
53. **Kagiava A.**, Sargiannidou I., Bashiardes S., Richter J., Christodoulou C., Gritti A., Kleopa K.A.; “Gene therapy for hypomyelinating leukodystrophy”; 23rd Meeting of the European Neurological Society; 8-11 June 2013; Barcelona, Spain (accepted as oral presentation).
54. Olympiou M., **Kagiava A.**, Sargiannidou I., Schiza N., Karaiskos C., Kleopas K.A.; "The effect of inflammation on glial gap junctions"; 26th Meeting of the Hellenic Society for Neuroscience, (November 29-December 1, 2013, Athens-Greece)
55. **Kagiava A.**, Sargiannidou I., Bashiardes S., Richter J., Schiza N., Christodoulou C., Gritti A. and Kleopas K.A.; "A quick method for targeted gene delivery to treat leukodystrophy and inherited neuropathies"; 26th Meeting of the Hellenic Society for Neuroscience, (November 29-December 1, 2013, Athens-Greece)
56. Schiza N., Sargiannidou I., **Kagiava A.**, Karaiskos C., Lapathitis G., Kleopa K.A.; “Transgenic rescue of oligodendrocyte gap junctions in a mouse model of hypomyelinating leukodystrophy”; 26th Meeting of the Hellenic Society for Neuroscience, (November 29-December 1, 2013, Athens-Greece)
57. **Kagiava A.**, Adamakis I.D. and Theophilidis G.; “The effects of rotenone on the function and structure of rat sciatic nerve fibres”; 8th Forum of European Neuroscience; July 14-18 2012; Barcelona-Spain
58. **Kagiava A.** and Theophilidis G.; “Oxaliplatin-induced hyperexcitation of rat sciatic nerve fibers: an intra-axonal study”; XIIth NeuroMediterranée Conference; 2-4 November 2012; Nicosia-Cyprus
59. Sargiannidou I., Bashiardes S., Richter J., **Kagiava A.**, Schiza N., Gritti A., Christodoulou C., Kleopa K.; “Gene therapy for inherited neuropathy”; XIIth NeuroMediterranée Conference; 2-4 November 2012; Nicosia-Cyprus
60. Sargiannidou I., **Kagiava A.**, Bashiardes S., Richter J., Schiza N., Christodoulou C., Gritti A., Kleopa K.A.; “Gene therapy for inherited neuropathy and leukodystrophy”; 3rd International Conference of the Cyprus Society of Human Genetics; 16-18 November 2012; Nicosia, Cyprus (invited oral presentation).
61. Zafeiridou G., Spilioti M., **Kagiava A.**, Petrakis A. and Karlovasitou A; "Effects of lacosamide, topiramate and phenytoin on the peripheral nervous system of the rat"; 10th European Congress on Epileptology London; 30 September–4 October 2012; UK

62. **Kagiava A.**, Kosmidis E.K., Theophilidis G. “Effects of oxaliplatin on the action potential of nerve axons of peripheral nervous system”; 17th Hellenic Conference of Clinical Oncology (April 14-16, 2011, Athens-Greece). Awarded with the second price
63. **Kagiava A.**, Aligizaki A., Katikou P., Theophilidis G. and Nikolaidis G.; “Assessment of the neurotoxic effects of palytoxin and palytoxin-like compounds produced by *Ostreopsis* species, affecting the Na⁺/K⁺-ATPase pump, using the isolated mouse sciatic nerve”; 7th Forum of European Neuroscience; July 3-7 2010; Amsterdam-The Netherlands. Awarded from FENS/IBRO
64. Tsigotjidou A., Bekiari C., **Kagiava A.**, Theophilidis G. and Emmanouilides C.E.; “An experimental study of peripheral neuropathy associated with Waldeström’s macroglobulinemia”; 14th Congress of the EHA; June 4-7 2009; Berlin-Germany
65. **Kagiava A.** and Theophilidis G.; “*In vitro* evaluation of the tolerance of the rat sciatic nerve under conditions of hypoxia and anoxia”; 6th Forum of European Neuroscience; July 12-16 2008; Geneva-Switzerland
66. **Kagiava A.** and Theophilidis G.; “Assessment of the effect of imidacloprid on the isolated rat sciatic nerve”; 30th Annual Scientific Meeting of EEBE (May 22-24, 2008, Thessaloniki-Greece)
67. **Kagiava A.** and Theophilidis G.; “The effect of insecticide imidacloprid, affecting the nicotinic cholinergic synapses, on the peripheral nerve fibers of the rat”; 22nd Annual Meeting of the Hellenic Society for Neuroscience (October 16-19, 2008, Athens-Greece)
68. Bekiari C., **Kagiava A.**, Emmanouilides C.E., Theophilidis G. and Tsigotjidou A.; “Assessing peripheral neuropathy associated with Waldeström’s macroglobulinemia” 22nd Annual Meeting of the Hellenic Society for Neuroscience (October 16-19, 2008, Athens-Greece)
69. N. Dabarakis, A. Veis, A. **Kagiava**, A. Fardi, O. Sintaki and G. Theophilidis; “Comparative *in vitro* study of the neurotoxicity of local anesthetics”; 42nd Annual Meeting of IADR-Continental European and Israeli Divisions; 26 – 29 September 2007; Thessaloniki-Greece
70. **Kagiava A.** and Theophilidis G.; “*In vitro* evaluation of the tolerance of the rat sciatic nerve under conditions of hypoxia and anoxia”; 29th Annual Scientific Meeting of EEBE (May 17-19, 2007, Kavala-Greece)
71. **Kagiava A.**, Tsigotjidou A., Emmanouilides C., Theophilidis G.; “Oxaliplatin: an anticancer drug inducing severe neuropathy by affecting the voltage-gated potassium channels in the nerve fibers of the peripheral nervous”; 21st Annual Meeting of the Hellenic Society for Neuroscience (November 30-December 1, 2007, Thessaloniki-Greece)
72. Dimitrios A. Adamos, **Alexia Kagiava**, Efstratios K. Kosmidis and George Theophilidis; “Decomposition of recorded compound action potential: axon diameter and conduction velocity distribution”; 21st Annual Meeting of the Hellenic Society for Neuroscience (November 30-December 1, 2007, Thessaloniki-Greece)
73. **Kagiava, A.** Tsigotjidou, T. Poutahidis, N. Foroglou and G. Theophilidis; “Evaluation of the regeneration in the three main nerve branches of the rat sciatic nerve”; 5th Forum of European Neuroscience; July 8-12 2006; Vienna-Austria
74. **Kagiava A.**, Tsigotjidou A., Emmanouilides C., Kosmidis E.K. and Theophilidis G.; “Assessment of oxaliplatin-induced acute neurotoxicity on the peripheral nervous system using the isolated sciatic nerve of the rat”; 20th Annual Meeting of the Hellenic Society for Neuroscience (September 29-October 1, 2006, Crete-Greece)
75. Adamos D.A., **Kagiava A.**, Theophilidis G. and Kosmidis E.K; “Conduction velocity distribution estimation from recorded compound action potentials”; 20th Annual Meeting of the Hellenic Society for Neuroscience (September 29-October 1, 2006, Crete-Greece)
76. N. Dabarakis, **A. Kagiava**, M. Vakalopoulou, and G. Theophilidis; “Effect of Prolonged Stretching of the Nerve *in vitro*”; 41st Annual Joint Meeting of the Continental European (CED) and Scandinavian (NOF) Divisions of the IADR; 14-17 September 2005
77. **A. Kagiava**, M. Vakalopoulou, N. Dabarakis, A. Geronikaki and G. Theophilidis; “Assessing the neuroprotective effects of oxygen on the isolated sciatic nerve of the rat. The role of temperature”; 19th Annual Meeting of the Hellenic Society for Neuroscience (September 30-October 2, 2005, Patra-Greece)